Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has been assigned a consensus rating of “Buy” from the twenty-eight ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and twenty have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $220.31.
Several equities analysts recently weighed in on VRTX shares. Citigroup lifted their target price on Vertex Pharmaceuticals from $205.00 to $225.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. BidaskClub downgraded Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Jefferies Financial Group set a $220.00 target price on Vertex Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, October 21st. Cowen reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, November 19th. Finally, Robert W. Baird set a $210.00 target price on Vertex Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, October 21st.
In other Vertex Pharmaceuticals news, EVP Amit Sachdev sold 5,000 shares of the firm’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $225.00, for a total transaction of $1,125,000.00. Following the sale, the executive vice president now directly owns 38,416 shares of the company’s stock, valued at $8,643,600. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Sangeeta N. Bhatia sold 8,379 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $166.80, for a total value of $1,397,617.20. Following the sale, the director now directly owns 7,810 shares in the company, valued at $1,302,708. The disclosure for this sale can be found here. Over the last three months, insiders have sold 295,475 shares of company stock worth $57,917,441. Insiders own 0.70% of the company’s stock.
Shares of VRTX stock traded down $1.57 on Monday, reaching $218.98. The stock had a trading volume of 1,341,499 shares, compared to its average volume of 1,219,827. The stock has a market cap of $56.57 billion, a P/E ratio of 77.38, a price-to-earnings-growth ratio of 2.01 and a beta of 1.49. Vertex Pharmaceuticals has a 1 year low of $151.80 and a 1 year high of $225.66. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.32 and a current ratio of 3.44. The company has a 50 day simple moving average of $210.36 and a 200 day simple moving average of $184.66.
Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Wednesday, October 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.87 by $0.36. The firm had revenue of $949.83 million for the quarter, compared to the consensus estimate of $942.90 million. Vertex Pharmaceuticals had a return on equity of 20.33% and a net margin of 59.24%. The company’s revenue for the quarter was up 21.1% on a year-over-year basis. During the same period last year, the business posted $1.09 EPS. On average, equities research analysts anticipate that Vertex Pharmaceuticals will post 3.72 earnings per share for the current fiscal year.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.
Further Reading: How to execute a trade ex-dividend strategy?
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.